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Abstract 1728  
 
 
QUALITY OF LIFE IN MACULAR DEGENERATION: AGE-RELATED MACULAR 
DEGENERATION ALLIANCE INTERNATIONAL (AMDAI) WHITE PAPER 
Jan Mitchell, Clare Bradley, Psychology, Royal Holloway, University of London, Egham, 
Surrey, United Kingdom  
 
 AIMS: The AMDAI sponsored us to review the literature and prepare a White Paper on 
QoL in macular degeneration (MD) with a view to increasing awareness of MD, reducing 
its impact and improving services for people with MD worldwide. METHODS:  A 
systematic review was conducted using electronic databases, conference proceedings 
and key journal hand search checks. RESULTS: MD, a chronic, largely untreatable eye 
condition, is the most common cause of blindness in the Western world. Shock of 
diagnosis, coupled with lack of information and support are a common experience. 
Incidence of depression is twice that found in the community-dwelling elderly. Some 
people feel suicidal. MD threatens independence, especially when comorbidity 
exacerbates functional decline. Rehabilitation, including low vision aid (LVA) provision 
and training, peer support and education, can improve functional and psychological 
outcomes but many people do not receive services likely to benefit them. Medical 
treatments, available for only some types of MD, can improve function but most limit 
progress of MD, at least for a time, rather than cure. The White Paper considers 
difficulties associated with inappropriate use of health status measures and 
misinterpretation of utility values as QoL measures: evidence suggests they have poor 
validity in MD.  CONCLUSIONS: There is considerable evidence for the major damage 
done to QoL by MD which is underestimated by health status and utility measures. 
Medical treatments are limited to a small proportion of people. However, much can be 
done to improve QoL by early diagnosis of MD with good communication of prognosis 
and continuing support. Support could include provision of LVAs, peer support including 
MD Society groups, education and effective help in adjusting to MD.The value of such 
provision is unlikely to be demonstrated by health status or utility measures. It is vital 
that appropriate measures of visual function and QoL be used in building a sound 
evidence base for the effectiveness of rehabilitation and treatment. 
